

Financial news for ORPN dated on 2019-03-11: 70 Biggest Movers From Friday

Financial news for ORPN dated on 2019-03-08: 50 Stocks Moving In Friday's Mid-Day Session

Financial news for ORPN dated on 2019-03-08: 64 Biggest Movers From Yesterday

Financial news for ORPN dated on 2019-03-06: Bioblast Announces Effectiveness Of 8-to-One Reverse Split

Financial news for ORPN dated on 2019-02-19: Bioblast Pharma Shares Resume Trade, Up 84.3%

Financial news for ORPN dated on 2019-02-19: Bioblast Pharma shares are trading higher after the company announced the sale of its Trehalose clinical development program to Seelos Therapeutics for an unconditional payment of \$3.5 million and a contingent payment of up to \$17 million, plus royalties.

Financial news for ORPN dated on 2019-02-19: Bioblast Pharma Announces Sale Of Its Trehalose Clinical Development Programs To Seelos Therapeutics; Unconditional Payment Of \$3.5M, Contingent Payment Of Up To \$17M Plus Royalties

Financial news for ORPN dated on 2019-02-19: 61 Biggest Movers From Friday

Financial news for ORPN dated on 2019-02-15: 52 Stocks Moving In Friday's Mid-Day Session

Financial news for ORPN dated on 2019-02-15: Bioblast Pharma shares are trading higher after the company announced a clinical collaboration with Team Sanfilippo to evaluate the safety and efficiency of Bioblast's treatment for Sanfilippo syndrome.

Financial news for ORPN dated on 2019-02-15: The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal

Financial news for ORPN dated on 2019-01-11: Bioblast Pharma Reports Receipt Of Nasdaq Notification Related To Minimum Shareholders' Equity Non Compliance; Co. Has Until Feb. 22, 2019 To Submit Plan To Regain Compliance To Nasdaq

Financial news for ORPN dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for ORPN dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for ORPN dated on 2018-11-21: 50 Biggest Movers From Yesterday

Financial news for ORPN dated on 2018-11-20: Mid-Afternoon Market Update: Dow Down 450 Points; Tarena International Shares Drop After Q3 Results

Financial news for ORPN dated on 2018-11-20: 36 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ORPN dated on 2018-11-20: Mid-Day Market Update: Crude Oil Down 5.5%; Bioblast Pharma Shares Spike Higher

Financial news for ORPN dated on 2018-11-20: Mid-Morning Market Update: Markets Open Lower; Target Earnings Miss Expectations

Financial news for ORPN dated on 2018-11-20: Bioblast Pharma shares are up 26.28% premarket after the company announced it will acquire Enlivex to advance a clinical state immunotherapeutic drug pipeline for treatment of life-threatening immune conditions.

Financial news for ORPN dated on 2018-11-19: Bioblast Pharma shares are up 43.7% after the company announced it will acquire Enlivex to advance a clinical state immunotherapeutic drug pipeline for treatment of life-threatening immune conditions.

Financial news for ORPN dated on 2018-11-19: Bioblast Pharma Shares Resume Trade, Up 35%

Financial news for ORPN dated on 2018-11-19: Bioblast Pharma Shares To Resume Trade At 4:45 p.m. EST

Financial news for ORPN dated on 2018-11-19: Bioblast Pharma To Acquire Enlivex Therapeutics Ltd. To Advance Clinical Stage Immunotherapeutic Drug Pipeline For Treatment Of Life-Threatening Diseases Sepsis, GvHD And Solid Tumors

Financial news for ORPN dated on 2018-11-19: Bioblast Pharma Shares Halted News Pending

Financial news for ORPN dated on 2018-08-08: Stocks Which Set New 52-Week Low Yesterday, August 7th

Financial news for ORPN dated on 2018-08-03: Stocks Which Set New 52-Week Low Yesterday, August 2nd

Financial news for ORPN dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for ORPN dated on 2018-07-27: Stocks Which Set New 52-Week Low Yesterday, July 26th:

Financial news for ORPN dated on 2018-07-27: Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

Financial news for ORPN dated on 2018-07-26: Bioblast Pharma Says 'working diligently to find [commercial] partner, as well as to enter into a merger agreement with a third party'

Financial news for ORPN dated on 2018-07-26: Stocks Which Set New 52-Week Low Yesterday, July 25th

Financial news for ORPN dated on 2018-05-21: 23 Stocks Moving In Monday's Pre-Market Session

Financial news for ORPN dated on 2018-05-21: 36 Biggest Movers From Friday

Financial news for ORPN dated on 2018-05-18: 26 Stocks Moving In Friday's Mid-Day Session

Financial news for ORPN dated on 2018-05-18: UPDATE: Bioblast CEO Price On Today's Price Action Tells Benzinga: 'We have no news, no pending news...This is a mystery to us...what usually happens is that at the end of the day the stock drifts down back to where it was at the close yesterday.'

Financial news for ORPN dated on 2018-05-18: Bioblast CEO Fred Price, Asked About Today's Price Action, Tells Benzinga He's Called The Company's Compliance Office This Morning And 'We know of nothing that would cause the volume or the stock to go up today.'

Financial news for ORPN dated on 2018-05-18: Bioblast Pharma Shares Up 21.6% On No Formal News; Shares Have Seen Similar Spikes Before, Most Likely Due To Low-Float Interest As Co. Has ~3.34M Shares Outstanding

Financial news for ORPN dated on 2018-05-08: Benzinga Pro's 6 Stocks To Watch Today

Financial news for ORPN dated on 2018-05-08: 31 Biggest Movers From Yesterday

Financial news for ORPN dated on 2018-01-22: 34 Biggest Movers From Friday

Financial news for ORPN dated on 2018-01-19: 28 Stocks Moving In Friday's Mid-Day Session

Financial news for ORPN dated on 2018-01-19: Bioblast Shares Up 34% For Session; On Wed., Co. CEO Reassured Benzinga No News To Justify Move, Noted Price Action Sometimes Happen But 'stock usually goes back to where it started within a day or so'

Financial news for ORPN dated on 2018-01-17: ICYMI: Shutterfly Downgrade, BioBlast Price Action, Blockchain ETFs

Financial news for ORPN dated on 2018-01-17: BioBlast CEO Calls Price Spike 'Bizarre'

Financial news for ORPN dated on 2018-01-17: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ORPN dated on 2018-01-17: Bioblast Pharma CEO Fred Price, On Recent Stock Volatility, Tells Benzinga 'I spoke to NASDAQ and told them we have no clue as to what's happening. This has happened twice before...stock usually goes back to where it started within a day or so.'

Financial news for ORPN dated on 2018-01-17: BZ NOTE: Bioblast Shares Saw Sharp Upside, Volatility On Jan. 5 Amid Social Media Mention Co.'s Ongoing Strategic Review Could Conclude 'Soon'

Financial news for ORPN dated on 2018-01-17: Bioblast Pharma Shares Halted On Circuit Breaker, Up 24.6%

Financial news for ORPN dated on 2018-01-05: Bioblast Pharma Shares Up 20+% On More

Than 4x Avg. Volume With Some Social Media Mention That Ongoing Strategic Alternative Review Could Be Concluded Soon

Financial news for ORPN dated on 2017-12-21: 46 Biggest Movers From Yesterday

Financial news for ORPN dated on 2017-12-20: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ORPN dated on 2017-12-20: Bioblast Pharma Shares Resume Trade, Pullback From Session Highs, Still Up 28.6% For Session

Financial news for ORPN dated on 2017-12-20: Bioblast Pharma Halted On Circuit Breaker, Up 32.8% At \$2.83

Financial news for ORPN dated on 2017-12-20: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ORPN dated on 2017-11-02: Bioblast Pharma Q3 EPS \$(0.32), No Sales

Financial news for ORPN dated on 2017-10-25: 40 Biggest Movers From Yesterday

Financial news for ORPN dated on 2017-10-12: 12 Stocks Moving In Thursday's After-Hours Session

Financial news for ORPN dated on 2017-10-12: 33 Stocks Moving In Thursday's Mid-Day Session

Financial news for ORPN dated on 2017-09-28: 18 Biggest Mid-Day Losers For Thursday

Financial news for ORPN dated on 2017-09-25: Mid-Day Market Update: Dow Drops Over 100 Points; Aradigm Shares Spike Higher

Financial news for ORPN dated on 2017-09-25: Mid-Morning Market Update: Markets Edge Lower; D. R. Horton Cuts Cash Flow Outlook

Financial news for ORPN dated on 2017-09-25: Bioblast's Previously Announces 5 to 1 Split Becomes Effective

Financial news for ORPN dated on 2017-08-04: Bioblast Pharma Reports Q2 EPS \$(0.10) vs \$(0.22) In Same Qtr. Last Year

Financial news for ORPN dated on 2017-06-05: Bioblast Pharma Shares to Resume Trade at 4:45 p.m. EDT

Financial news for ORPN dated on 2017-06-05: UPDATE: Bioblast Has Engaged JSB-Partners Lead Strategic Alternatives Process

Financial news for ORPN dated on 2017-06-05: Bioblast Pharma Reports Will Seek Strategic Alternatives, Including Partnerships, Merger Opportunities

Financial news for ORPN dated on 2017-06-05: Bioblast Pharma Shares Halted News Pending

Financial news for ORPN dated on 2017-05-26: Bioblast Pharma Reports Q1 EPS \$(0.16) vs \$(0.29) Est.

Financial news for ORPN dated on 2017-04-17: Bioblast Pharma Announces Nasdaq Notice Of Listing Deficiency And Minimum Bid Requirements

Financial news for ORPN dated on 2017-04-06: Bioblast Pharma Reports Termination of Securities Offering Due To Adverse Market Conditions

Financial news for ORPN dated on 2017-02-24: Bioblast Pharma Reports Q4 EPS \$(0.19) vs. \$(0.27) Est.

Financial news for ORPN dated on 2017-02-01: Bioblast Pharma Provides Clinical Update On Trehalose, Post-hoc Analysis From Phase 2a Open Label OPMD Trial Showed Significant Reduction In Drinking Time Compared To Baseline

Financial news for ORPN dated on 2017-01-18: Bioblast Reports Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3

Financial news for ORPN dated on 2016-11-29: 15 Biggest Mid-Day Losers For Tuesday

Financial news for ORPN dated on 2016-11-29: Bioblast Pharma Q3 EPS \$(0.28), No Revenue

Financial news for ORPN dated on 2016-09-12: Bioblast Pharma Reports Results of a Clinical Trial of Trehalose in Oculopharyngeal Muscular Dystrophy (OPMD) Patients

Financial news for ORPN dated on 2016-08-25: Bioblast Pharma Reports Q2 EPS \$(0.22) vs. Est. \$(0.27)

Financial news for ORPN dated on 2016-07-25: Bio Blast Pharma Shares Spike to High of \$1.80 on Volume

Financial news for ORPN dated on 2016-06-09: Bioblast Pharma Expects to Start Phase 2b Trial in 2H 2016

Financial news for ORPN dated on 2016-05-25: Bioblast Pharma Reports Q1, Loss of \$0.32 per share, Net Loss Of \$4.6M

Financial news for ORPN dated on 2016-04-18: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for ORPN dated on 2016-04-15: Mid-Afternoon Market Update: Infosys Rises Following Q4 Results; Ixia Shares Slide

Financial news for ORPN dated on 2016-04-15: Mid-Day Market Update: Super Micro Computer Drops Following Weak Guidance; Bio Blast Pharma Shares Surge

Financial news for ORPN dated on 2016-04-15: Mid-Morning Market Update: Markets Edge Lower; Citigroup Profit Tops Views

Financial news for ORPN dated on 2016-04-15: 10 Stocks Moving In Friday's Pre-Market Session

Financial news for ORPN dated on 2016-04-15: Bio Blast Gains 9%, Company Will Present Final Phase 2 Trial Data At Industry Conference

Financial news for ORPN dated on 2016-04-14: After-Hours Recap: Big Banks, Liquidity Services's DoD Deal, Haemonetics' CFO & More

Financial news for ORPN dated on 2016-04-14: BioBlast Pharma Reports Will Present Final HOPEMD Phase 2 Trial of Trehalose in Oculopharyngeal Muscular Dystrophy at AAN

Financial news for ORPN dated on 2016-04-14: 10 Stocks Moving In Thursday's Pre-Market Session

Financial news for ORPN dated on 2016-04-07: 10 Stocks Moving In Thursday's Pre-Market Session

Financial news for ORPN dated on 2016-03-23: Sabby Reports 6.17% Passive Stake in Bio Blast Pharma

Financial news for ORPN dated on 2016-03-17: Mid-Afternoon Market Update: Dow Rises Over 1%; Jabil Circuit Shares Decline Following Weak Results

Financial news for ORPN dated on 2016-03-17: Mid-Day Market Update: FedEx Surges On Earnings Beat; Guess? Shares Drop

Financial news for ORPN dated on 2016-03-17: Mid-Morning Market Update: Markets Mostly Lower; Michaels Tops Q4 Expectations

Financial news for ORPN dated on 2016-03-17: 10 Stocks Moving In Thursday's Pre-Market Session

Financial news for ORPN dated on 2016-03-16: Mid-Afternoon Market Update: Dow Gains 125 Points; Crude Oil Up 5%

Financial news for ORPN dated on 2016-03-16: Mid-Day Market Update: Peabody Energy Slides Amid Possible Bankruptcy; Bio Blast Pharma Shares Surge

Financial news for ORPN dated on 2016-03-16: Mid-Morning Market Update: Markets Edge Higher; Oracle Earnings Top Views

Financial news for ORPN dated on 2016-03-16: UPDATE: BioBlast Pharma Improvements Observed In Multiple Secondary Efficacy Endpoints Related To Dysphagia, Muscle Strength, And Function

Financial news for ORPN dated on 2016-03-16: BioBlast Pharma Reports Positive Phase 2 HOPEMD Open-Label Clinical Study Of Trehalose 90mg/ml in OPMD, Was observed To Be Safe & Well-Tolderated

Financial news for ORPN dated on 2016-02-23: BioBlast Pharma Reports Q4 \$(0.34) vs. Est. \$(0.25)

Financial news for ORPN dated on 2016-01-28: Benzinga's Top Initiations

Financial news for ORPN dated on 2016-01-28: H.C. Wainwright Initiates Coverage on Bio Blast Pharma at Buy, Announces \$25.00 PT

Financial news for ORPN dated on 2015-12-09: Bioblast Pharma Gives Update, Says Does Not Plan to Conduct Phase 3 Cabaletta Study in 2016, Will Conduce Phase 2B

Financial news for ORPN dated on 2015-11-17: BioBlast Reports Q3 EPS (\$0.25) vs. Est. (\$0.29)

Financial news for ORPN dated on 2015-11-17: BioBlast Pharma Reports Q3 EPS \$(0.25) Vs Est \$(0.29)

Financial news for ORPN dated on 2015-10-27: Morning Market Gainers

Financial news for ORPN dated on 2015-10-27: Benzinga's Top #PreMarket Gainers

Financial news for ORPN dated on 2015-10-09: BioBlast Pharma Names Theresa (Terri) Stevens as Chief Corporate Development Officer

Financial news for ORPN dated on 2015-10-09: BioBlast Pharma Names Theresa Stevens Chief Corporate Development Officer

Financial news for ORPN dated on 2015-09-10: BioBlast Pharma. Names Paul Firuta Chief Commercial Officer

Financial news for ORPN dated on 2015-08-21: BioBlast Pharma Reports Q2 EPS \$(0.26) vs. Est. \$(0.28)

Financial news for ORPN dated on 2015-06-29: BioBlast Pharma Given Orphan Drug Designation From the European Commission for Cabaletta for the Treatment of Spinocerebellar Ataxia

Financial news for ORPN dated on 2015-06-25: BioBlast Pharma Receives Orphan Drug Designation From the European Commission for Cabaletta for the Treatment of Oculopharyngeal Muscular Dystrophy

Financial news for ORPN dated on 2015-06-22: BioBlast Pharma Announces Positive Preclinical Results For Spinal Muscular Atrophy Drug

Financial news for ORPN dated on 2015-06-15: Roth Capital Maintains Buy on Bio Blast Pharma, Raises PT to \$25.00

Financial news for ORPN dated on 2015-06-15: BioBlast Announces the Start of a Phase 3 Study for Cabaletta in Oculopharyngeal Muscular Dystrophy

Financial news for ORPN dated on 2015-05-19: Bio Blast Pharma Reports Reports Q1 EPS \$0.23 Vs Prior \$0.06

Financial news for ORPN dated on 2015-05-19: Bio Blast Pharma Q1 EPS -\$0.23 vs -\$0.25 est

Financial news for ORPN dated on 2015-04-09: Morning Market Gainers

Financial news for ORPN dated on 2015-04-09: Bioblast Pharma Announces Fast Track Designation

Financial news for ORPN dated on 2015-04-09: BioBlast Pharma Granted Fast Track Designation by the FDA for Cabaletta in Oculopharyngeal Muscular Dystrophy (OPMD)

Financial news for ORPN dated on 2015-03-30: BioBlast Pharma Announces Positive in vivo Preclinical Proof-of-Concept Results Of Cabaletta Platform in Spinocerebellar Ataxia Type 3 (SCA3)

Financial news for ORPN dated on 2015-03-26: BioBlast Pharma Reports Positive Preclinical Proof-of-Concept Results of Its Novel Mitochondrial Protein Replacement Platform in Friedreich's Ataxia

Financial news for ORPN dated on 2015-03-12: BioBlast Receives Clearance To Commence Cabaletta Clinical Trial For OPMD Treatment

Financial news for ORPN dated on 2015-02-17: BioBlast Pharma Reports Q4 Loss of \$0.22/Share vs Loss of \$0.16/Share Est.

Financial news for ORPN dated on 2015-02-02: Bio Blast Pharma Names Colin Foster President, CEO

Financial news for ORPN dated on 2015-01-08: Bio Blast Pharma Says Preliminary Results Show 9 of 11 Patients See Symptom Improvement

Financial news for ORPN dated on 2014-12-17: BioBlast Receives Notice of Patent Issuance From USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich's Ataxia

Financial news for ORPN dated on 2014-11-19: Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta For The Treatment Of Spinocerebellar Ataxia Type 3

Financial news for ORPN dated on 2014-09-17: BioBlast Pharma Announces Positive Preclinical and Clinical Pharmacokinetic Results

Financial news for ORPN dated on 2014-08-29: Morning Market Losers

Financial news for ORPN dated on 2014-08-26: Winners & Losers From Monday, August 25

Financial news for ORPN dated on 2014-08-25: Morning Market Movers

Financial news for ORPN dated on 2014-08-25: Oppenheimer Initiates Coverage on Bio Blast Pharma Ltd at Outperform, Announces \$32.00 PT

Financial news for ORPN dated on 2014-08-25: Roth Capital Initiates Coverage on Bio Blast Pharma Ltd at Buy, Announces \$15.00 PT

Financial news for ORPN dated on 2014-08-18: BioBlast Receives Notice Of Allowance From USPTO For Its Novel Fusion Protein-Based Platform For The Treatment Of Friedrich's Ataxia

Financial news for ORPN dated on 2014-08-04: IPO Outlook: Can A \$200 Million IPO Be The Answer After A Lackluster Week?

Financial news for ORPN dated on 2014-07-31: IPO for Bio Blast Pharma Opens at \$10.90/Share, Priced at \$11

Financial news for ORPN dated on 2014-07-31: Waiting on 11 IPOs This Morning

Financial news for ORPN dated on 2014-07-30: Bio Blast Pharma Prices 3.2M Share IPO at \$11/Share

Financial news for ORPN dated on 2014-07-28: IPO Lookout: Busy Week Brings The Biggest IPO Since Facebook

Financial news for ORPN dated on 2014-04-08: Bio Blast Pharma Files IPO of Undisclosed Number of Shares